← brief for 2026-10-20 · Slowing decline

Is SGLT2 inhibitor therapy recommended for patients with diabetes and chronic kidney disease classified as G3aA1?

Article No results yet Not peer reviewed

Key takeaways

This item discusses a common kidney drug for people with diabetes. It is a record on a data repository, not a new study with results. There are no new findings to report here.

Who did this work

Tripdatabase

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-10-19
https://doi.org/10.5281/zenodo.23472396